test

Erin O'Connor

@Fairmount Funds Management Llc

Latest period2024 - Q3ReportedManaged Assets$1.233BTotal holdings15
Assets growth rate39.34%Assets growth rate (2-Q avg)17.91%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Fairmount Funds Management Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 15 positions.

Assets under management

The assets under management (AUM) of Fairmount Funds Management Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.233B in assets, with a quarterly growth rate of 39.34% and a 2-quarter average growth rate of 17.91%. The portfolio is managed by Erin O'Connor, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
AXSMAxsome Therapeutics Inc
Recent Activity
17.2%
$212.1M
2.36M shares@ $89.88 avg price
NUVLNuvalent Inc
Recent Activity
Decreased -12.34%
14%
$172.587M
1.687M shares@ $102.3 avg price
APGEApogee Therapeutics Inc
Recent Activity
9.76%
$120.338M
2.049M shares@ $58.75 avg price
SYRESpyre Therapeutics Inc
Recent Activity
9.59%
$118.172M
4.018M shares@ $29.41 avg price
ELVNEnliven Therapeutics Inc
Recent Activity
6.64%
$81.799M
3.203M shares@ $25.55 avg price
KNSAKiniksa Pharmaceuticals Intl
Recent Activity
6.5%
$80.089M
3.205M shares@ $25.0 avg price
ORKAOruka Therapeutics Inc
Recent Activity
New Position
6.39%
$78.724M
3.212M shares@ $24.51 avg price
VRDNViridian Therapeutics Inc
Recent Activity
Increased 86.69%
6.36%
$78.392M
3.446M shares@ $22.76 avg price
DNTHDianthus Therapeutics Inc
Recent Activity
Decreased -2.24%
6%
$73.945M
2.701M shares@ $27.39 avg price
COGTCogent Biosciences Inc
Recent Activity
5.46%
$67.237M
6.226M shares@ $10.81 avg price